Genmab

Genmab puts down $54M for immunotherapy collaboration — ready to spend millions more
Genmab puts down $54M for immunotherapy collaboration — ready to spend millions more
Endpoints
Genmab
JNJ
Europe
cancer immunotherapy
Immatics
Flag link:
Seattle Genetics Doses First Patient In Ph II Trial of Antibody-drug Conjugate in Multiple Solid Tumors
Seattle Genetics Doses First Patient In Ph II Trial of Antibody-drug Conjugate in Multiple Solid Tumors
CP Wire
Seattle Genetics
colorectal cancer
non-small cell lung cancer
pancreatic cancer
head and neck cancer
cervical cancer
tisotumab vedotin
Genmab
clinical trials
Flag link:
Roche Up, J&J Down as Cancer Drug Combos Yield More Mixed Results
Roche Up, J&J Down as Cancer Drug Combos Yield More Mixed Results
Xconomy
clinical trials
Roche
Genentech
Genmab
JNJ
cancer
Tecentriq
Darzalex
Flag link:
Danish biotech Genmab hit by ending of trial using key cancer drug
Danish biotech Genmab hit by ending of trial using key cancer drug
Reuters
Genmab
JNJ
Janssen
Darzalex
Flag link:
Genmab hits roadblock in non-Hodgkin lymphoma
Genmab hits roadblock in non-Hodgkin lymphoma
Biopharma Dive
Genmab
non-Hodgkin's lymphoma
Arzerra
clinical trials
Flag link:
Novartis, feeling the heat from head-to-head rivals, pulls Arzerra outside the U.S.
Novartis, feeling the heat from head-to-head rivals, pulls Arzerra outside the U.S.
Fierce Pharma
Novartis
Arzerra
Genmab
CLL
chronic lymphocytic leukemia
Flag link:
Genmab and J&J 'love' partnership as some ponder takeover
Genmab and J&J 'love' partnership as some ponder takeover
Yahoo/Reuters
Genmab
JNJ
M&A
Darzalex
Flag link:
Seven years in the making, Seattle Genetics picks up early option on Genmab’s ADC effort
Seven years in the making, Seattle Genetics picks up early option on Genmab’s ADC effort
Endpoints
Seattle Genetics
Genmab
antibody-drug conjugate
tisotumab vedotin
Flag link:
Genmab gains on promising early success for daratumumab PhIII in multiple myeloma, but questions linger
Genmab gains on promising early success for daratumumab PhIII in multiple myeloma, but questions linger
Endpoints
Genmab
daratumumab
Darzalex
Multiple Myeloma
clinical trials
Flag link:
Johnson & Johnson's 3 Biggest Sources of Growth Over the Next 10 Years
Johnson & Johnson's 3 Biggest Sources of Growth Over the Next 10 Years
Motley Fool
JNJ
devices
baby boomers
specialty medicines
M&A
Genmab
Imbruvica
Flag link:
Looking for Darzalex sales expansion, J&J, Genmab hit a wall in lymphoma
Looking for Darzalex sales expansion, J&J, Genmab hit a wall in lymphoma
Fierce Pharma
Darzalex
JNJ
Genmab
non-Hodgkin's lymphoma
Flag link:
Johnson & Johnson May Already Have Its Remicade Replacement Well in Hand
Johnson & Johnson May Already Have Its Remicade Replacement Well in Hand
Motley Fool
JNJ
Remicade
Darzalex
Genmab
Multiple Myeloma
Flag link:
Gilead licenses bi-specific tech from Danish biotech Genmab
Gilead licenses bi-specific tech from Danish biotech Genmab
BioPharma Dive
Gilead Sciences
Genmab
HIV
Flag link:
Novartis stops PhIII trial of Genmab's Arzerra after buying rights from GSK
Novartis stops PhIII trial of Genmab's Arzerra after buying rights from GSK
Fierce Biotech
Novartis
Genmab
Arzerra
GSK
pemphigus vulgaris
Flag link:
J&J nabs an early OK for 'breakthrough' multiple myeloma blockbuster contender Darzalex
J&J nabs an early OK for 'breakthrough' multiple myeloma blockbuster contender Darzalex
Fierce Biotech
JNJ
Multiple Myeloma
daratumumab
FDA
Darzalex
Genmab
Flag link:
J&J positions blockbuster contender daratumumab for a multiple myeloma showdown
J&J positions blockbuster contender daratumumab for a multiple myeloma showdown
Fierce Biotech
JNJ
daratumumab
Multiple Myeloma
Kyprolis
Amgen
Genmab
elotuzumab
AbbVie
Bristol-Myers Squibb
Flag link:
Novo Nordisk ties the R&D knot with Genmab, and they're not focused on cancer
Novo Nordisk ties the R&D knot with Genmab, and they're not focused on cancer
Fierce Biotech
Genmab
Novo Nordisk
R&D
Flag link:
Novartis files leukemia drug Arzerra in the EU
Novartis files leukemia drug Arzerra in the EU
BioPharma Dive
Novartis
Arzerra
Europe
Genmab
CLL
chronic lymphocytic leukemia
Flag link:
Genmab shares rise on cancer drug's FDA license application
Genmab shares rise on cancer drug's FDA license application
Yahoo/Reuters
Genmab
FDA
JNJ
daratumumab
Multiple Myeloma
Flag link:
Amgen hands off an IL-15 drug--strings attached--for upstart effort on celiac disease
Amgen hands off an IL-15 drug--strings attached--for upstart effort on celiac disease
Fierce Biotech
Amgen
celiac disease
AMG 714
Genmab
Flag link:

Pages